Enanta Pharmaceutica (ENTA) Stock Price, Quote & News

Company Profile

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human cor...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 607 0800

Fax: 617 607 0530

Website: www.enanta.com

Address:

4 Kingsbury Avenue, Watertown, United States

OfficialStocktwitsUser Feb. 20 at 2:04 PM

$ENTA RSI: 67.63, MACD: 0.1056 Vol: 0.51, MA20: 13.43, MA50: 14.02 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

LiquidityRisk Feb. 20 at 1:23 PM

$ENTA Enanta Pharmaceuticals generates royalties from antiviral drugs. Pipeline progress drives upside. Cash reserves support development.

0 · Reply

Doozio Feb. 20 at 4:34 AM

$ONC $ENTA 🐒🍌🧠⏰♾️? Fook it!

0 · Reply

Doozio Feb. 20 at 4:15 AM

👁️ $SPY FRYday $ENTA $NVDA going chop chop huckleberries 🐒🍌🧠⏰♾️.

0 · Reply

NoEmotionzTrade Feb. 19 at 3:11 AM

AGAE small cap math is simple tiny float cap, strong cash position, real partnership backing, bullish technical cross forming. Break.40 and momentum could carry this toward .50+. and then 1+ just like OLB $ENTA $VNDA $ZNTL $SANA

0 · Reply

RuleBasedReturns Feb. 18 at 4:24 PM

$ENTA Enanta Pharmaceuticals focuses on virology with royalty-based revenue streams. Pipeline execution and partner success drive earnings volatility. Cash position supports development.

0 · Reply

judgeyoung2 Feb. 17 at 12:25 PM

$OCUL i could see this being similar to $ENTA with a bounce to green

0 · Reply

justiceforb_85 Feb. 11 at 5:52 PM

$ENTA wouldn't be surprised to see a BO for RSV franchise prior to P3. This is really undervalued on that alone.

0 · Reply

AngelaWallace856 Feb. 11 at 5:04 PM

$ENTA Enanta Pharmaceuticals; biotech (antivirals, NASH); clinical setbacks; pipeline reset; cash runway.

0 · Reply

prismmarketview Feb. 10 at 11:14 PM

We’ve added Enanta Pharmaceuticals $ENTA to the PRISM Pharmaceuticals Index as its lead drug, zelicapavir, advances toward Phase 3 for RSV, a serious respiratory virus that impacts infants, older adults, and high-risk patients. With strong Phase 2 data, a well-funded balance sheet, and an expanding immunology pipeline, ENTA offers asymmetric upside tied to both near-term RSV catalysts and longer-term immune disease opportunities. https://prismmarketview.com/companies/enanta-pharmaceuticals-inc/

0 · Reply

Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual Meeting

Feb 9, 2026, 4:01 PM EST - 11 days ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025

Jan 14, 2026, 8:25 PM EST - 5 weeks ago

Enanta Pharmaceuticals, Inc. (ENTA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 8, 2026, 7:00 AM EST - 6 weeks ago

Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook

Jan 5, 2026, 7:00 AM EST - 6 weeks ago

Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 19, 2025, 3:01 PM EST - 3 months ago

Enanta: Maintaining Buy Rating Based On Zelicapavir Potential In RSV Development

Nov 17, 2025, 4:01 PM EST - 3 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2025

Nov 4, 2025, 7:00 AM EST - 3 months ago

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

Oct 20, 2025, 7:00 AM EDT - 4 months ago

Enanta Pharmaceuticals Presents New Data for Zelicapavir, its N-Protein Inhibitor, and EDP-323, its L-Protein Inhibitor, Both in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Oct 7, 2025, 7:00 AM EDT - 4 months ago

Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025

Oct 2, 2025, 4:01 PM EDT - 5 months ago

Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Oct 1, 2025, 8:16 AM EDT - 5 months ago

Cal-Maine Foods Posts Downbeat Earnings, Joins Enanta Pharmaceuticals, AAR And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

CALM

Sep 30, 2025, 9:00 PM EDT - 5 months ago

Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

Sep 30, 2025, 4:11 PM EDT - 5 months ago

Enanta Pharmaceuticals Announces Proposed Public Offering of Common Stock

Sep 29, 2025, 3:47 PM EDT - 5 months ago

Enanta Pharmaceuticals, Inc. - Special Call

Sep 29, 2025, 2:40 PM EDT - 5 months ago

Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change

Sep 29, 2025, 6:30 AM EDT - 5 months ago

Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Sep 26, 2025, 4:01 PM EDT - 5 months ago

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults

Sep 3, 2025, 6:00 AM EDT - 6 months ago

Enanta Pharmaceuticals Announces the Passing of its Beloved and Respected Longtime Chief Financial and Administrative Officer Paul J. Mellett Jr.

Aug 21, 2025, 7:00 AM EDT - 6 months ago

Enanta Pharmaceuticals to Participate in September Investor Conferences

Aug 20, 2025, 7:00 AM EDT - 6 months ago

Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union

Aug 11, 2025, 4:02 PM EDT - 6 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025

Aug 5, 2025, 7:00 AM EDT - 7 months ago

Enanta Pharmaceuticals to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Jul 15, 2025, 7:00 AM EDT - 7 months ago

Enanta Pharmaceuticals to Participate in Baird's Biotech Discovery Series

Jun 11, 2025, 12:34 PM EDT - 9 months ago

Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

May 27, 2025, 7:00 AM EDT - 9 months ago

Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025, 7:00 AM EDT - 9 months ago

Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

May 12, 2025, 4:01 PM EDT - 10 months ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

Apr 8, 2025, 7:00 AM EDT - 11 months ago

Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025

Mar 17, 2025, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13th International RSV Symposium

Feb 10, 2025, 4:01 PM EST - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

Jan 8, 2025, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 24, 2024, 7:00 AM EST - 1 year ago

Enanta Pharmaceuticals to Appeal Ruling Related to ‘953 Patent Infringement Lawsuit

Dec 9, 2024, 6:30 AM EST - 1 year ago

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Dec 6, 2024, 5:00 PM EST - 1 year ago

Enanta Pharmaceuticals to Present Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for Respiratory Syncytial Virus (RSV)

Nov 25, 2024, 4:01 PM EST - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024

Sep 26, 2024, 6:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infected With Respiratory Syncytial Virus (RSV)

Sep 3, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate in Investor Conferences in September

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter

May 29, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference

May 7, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Participate at the JMP Securities Life Sciences Conference

May 6, 2024, 8:34 PM EDT - 1 year ago

Enanta Pharmaceuticals, Inc. (ENTA) Q2 2024 Earnings Call Transcript

May 6, 2024, 4:01 PM EDT - 1 year ago

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET

Apr 30, 2024, 7:10 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 30, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

Apr 29, 2024, 7:00 AM EDT - 1 year ago

Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024

Apr 17, 2024, 7:00 AM EDT - 2 years ago

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Mar 6, 2024, 7:00 AM EST - 2 years ago

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Feb 7, 2024, 10:04 PM EST - 2 years ago

Enanta Pharmaceuticals, Inc. (ENTA) Q1 2024 Earnings Call Transcript

OfficialStocktwitsUser Feb. 20 at 2:04 PM

0 · Reply

LiquidityRisk Feb. 20 at 1:23 PM

$ENTA Enanta Pharmaceuticals generates royalties from antiviral drugs. Pipeline progress drives upside. Cash reserves support development.

0 · Reply

Doozio Feb. 20 at 4:34 AM

$ONC $ENTA 🐒🍌🧠⏰♾️? Fook it!

0 · Reply

Doozio Feb. 20 at 4:15 AM

👁️ $SPY FRYday $ENTA $NVDA going chop chop huckleberries 🐒🍌🧠⏰♾️.

0 · Reply

NoEmotionzTrade Feb. 19 at 3:11 AM

0 · Reply

RuleBasedReturns Feb. 18 at 4:24 PM

$ENTA Enanta Pharmaceuticals focuses on virology with royalty-based revenue streams. Pipeline execution and partner success drive earnings volatility. Cash position supports development.

0 · Reply

judgeyoung2 Feb. 17 at 12:25 PM

$OCUL i could see this being similar to $ENTA with a bounce to green

0 · Reply

justiceforb_85 Feb. 11 at 5:52 PM

$ENTA wouldn't be surprised to see a BO for RSV franchise prior to P3. This is really undervalued on that alone.

0 · Reply

AngelaWallace856 Feb. 11 at 5:04 PM

$ENTA Enanta Pharmaceuticals; biotech (antivirals, NASH); clinical setbacks; pipeline reset; cash runway.

0 · Reply

prismmarketview Feb. 10 at 11:14 PM

0 · Reply

Estimize Feb. 10 at 9:00 PM

Wall St is expecting -0.57 EPS for $ENTA Q2 [Reporting 05/11 AMC] http://www.estimize.com/intro/enta?chart=historical&metric_name=eps&utm_c

0 · Reply

ParadiseProfit Jan. 26 at 2:43 AM

$ENTA Extended Cash Runway & Capital Raises…

1 · Reply

ParadiseProfit Jan. 26 at 2:42 AM

$ENTA The company is also advancing its immunology pipeline (STAT6, KIT inhibitors) and RSV programs, offering diversification beyond royalties…

0 · Reply

ParadiseProfit Jan. 26 at 2:41 AM

$ENTA oral RSV therapeutic zelicapavir has shown positive signs in Phase 2b studies (e.g., faster symptom resolution and safety signals), which supports longer-term development potential…

0 · Reply

ParadiseProfit Jan. 26 at 2:40 AM

$ENTA

0 · Reply

DimebagDarrell_ Jan. 22 at 11:56 PM

$ENTA 🤔

0 · Reply

NVDAMillionaire Jan. 20 at 8:46 PM

$ENTA Really good write-up that perfectly summarizes ENTA's present situation. So if you want to bring your ENTA knowledge up to date or just discover ENTA, this is required reading. https://everyticker.com/quote/ENTA/analysis/enanta-s-dueling-timelines-declining-royalties-vs-uncertain-pipeline-payoffs-nasdaq-enta

0 · Reply

BillionerOfKing Jan. 16 at 7:45 PM

$ENTA Current Stock Price: $12.74 Contracts to trade: $10 ENTA Jan 16 2026 Call Entry: $1.75 Exit: $2.71 ROI: 55% Hold ~31 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

garygb Jan. 3 at 8:08 PM

$ENTA Smart money play

0 · Reply

Doozio Dec. 26 at 3:49 PM

$XBI not if YO $EPRX yoself as a $DRUG addict $ENTA 🐒🍌🧠⏰♾️.

0 · Reply

justiceforb_85 Dec. 23 at 1:31 AM

$ENTA continues to impress. MC is way too low for the leader in RSV anti-viral space.

0 · Reply

Doozio Dec. 22 at 10:18 PM

Wen a new 🧠 $DAWN is $ENTA 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	406.27M
Revenue (ttm)	65.32M
Net Income (ttm)	-81.89M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-125.37%
Debt to Equity Ratio	0.00

Volume	435,600
Avg Vol	286,242
Day's Range	N/A - N/A
Shares Out	29.02M
Stochastic %K	19%
Beta	0.98
Analysts	Strong Sell
Price Target	$16.83